FIELD: pharmaceutics.
SUBSTANCE: group of inventions relates to pharmaceutical industry, namely a method for treating tumor and to a method for enhancing antitumor effect. The method for treating tumor includes injection of 1~1000 mg/m2/day of paclitaxel and 1~2000 mg/m2/day of 1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)cytosine methane sulfonate to a subject, wherein applicable quantity of 1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)cytosine methane sulfonate is from 0.01 to 100-fold of molar quantity of paclitaxel. The method for enhancing antitumor effect of paclitaxel includes injection of 1~2000 mg/m2/day of 1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)cytosine methane sulfonate.
EFFECT: above-mentioned methods are effective for treating tumor and enhancing antitumor effect of paclitaxel.
5 cl, 3 dwg, 2 tbl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
NEW DERIVATIVES OF PEG | 2015 |
|
RU2697551C2 |
SALT OF 1-(2-DEOXY-2-FLUORO-4-THIO-BETA-D-ARABINOFURANOZIL)CYTOSINE | 2013 |
|
RU2600734C2 |
COMBINATION THERAPY WITH ANTITUMOR ALKALOID | 2018 |
|
RU2757373C2 |
COMBINATION THERAPY WITH ANTITUMOR ALKALOID | 2011 |
|
RU2743643C2 |
LIQUID MEDICINAL PREPARATION | 2017 |
|
RU2715240C1 |
AGENT INTENSIFYING ACTION OF ANTI-CANCER AGENTS | 2012 |
|
RU2589713C2 |
COMBINATION THERAPY WITH AN ANTITUMOR ALKALOID | 2011 |
|
RU2605335C2 |
ANTI-TUMOUR COMBINATIONS MTOR INHIBITORS, HERCEPTIN AND/OR HKI-272 | 2006 |
|
RU2451524C2 |
PHARMACEUTICAL COMPOSITION ELICITING IMPROVED ANTITUMOR EFFECT AND/OR REDUCED ADVERSE EFFECTS AND COMPRISING ANTITUMOR AGENT AND DERIVATIVE OF HYDROXAMIC ACID | 1998 |
|
RU2254129C2 |
ANTITUMOUR COMBINATIONS WITH MTOR INHIBITORS, HERCEPTIN AND/OR HKI-272 | 2012 |
|
RU2632104C2 |
Authors
Dates
2021-07-23—Published
2017-08-30—Filed